ArticleCell death & disease2019

ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7.

Ting Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.